Poly Medicure Ltd. (POLYMED) fundamentals
Poly Medicure Ltd. is a listed company in Healthcare Equipment & Supplies, part of the Healthcare sector, listed on the NSE as POLYMED (ISIN INE205C01021). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Poly Medicure Ltd. does
Poly Medicure Limited is an India-based medical device manufacturer and exporter, with its products sold in over 125 countries. The Company is primarily in the business of manufacturing and selling medical devices. With a portfolio of over 200 medical devices and more than 330 patents, the Company offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anesthesia and respiratory care, urology, and surgery and wound management. Its products consist of an I.V. cannula, arterial cannula, prefilled syringe, nasogastric feeding tube, gastro-duodenal feeding tube, umbilical catheter, irrigation sets, urine drainage catheters and others.
Valuation and market data
| Last close | ₹1738.50 |
|---|---|
| Market capitalisation | ₹17,540 crore |
| Enterprise value | ₹17,682 crore |
| P/E (TTM) | 54.69 |
| Price to book | 5.57 |
| Price to sales (TTM) | 5.11 |
| Book value per share | ₹312.15 |
| Dividend yield | 40.26% |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Listed since | Wed Dec 07 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,782 crore | ₹448 crore | ₹336 crore | 33.15 |
| Mar 2025 | ₹1,692 crore | ₹443 crore | ₹331 crore | 33.40 |
| Mar 2024 | ₹1,365 crore | ₹335 crore | ₹252 crore | 26.24 |
| Mar 2023 | ₹1,104 crore | ₹237 crore | ₹179 crore | 18.67 |
| Mar 2022 | ₹918 crore | ₹195 crore | ₹146 crore | 15.23 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 62.4% |
|---|---|
| Foreign institutions (FII) | 5.6% |
| Mutual funds | 9.6% |
| Other domestic institutions | 6.5% |
| Retail and others | 15.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.